SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001347178-19-000014
Filing Date
2019-08-01
Accepted
2019-08-01 07:04:26
Documents
86
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vnda630201910q.htm   iXBRL 10-Q 1460047
2 EXHIBIT 31.1 vndaex311630201910q.htm EX-31.1 13571
3 EXHIBIT 31.2 vndaex312630201910q.htm EX-31.2 13539
4 EXHIBIT 32.1 vndaex321630201910q.htm EX-32.1 9465
  Complete submission text file 0001347178-19-000014.txt   7077221

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20190630.xsd EX-101.SCH 54534
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20190630_cal.xml EX-101.CAL 98691
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20190630_def.xml EX-101.DEF 224997
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20190630_lab.xml EX-101.LAB 653564
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20190630_pre.xml EX-101.PRE 407505
10 EXTRACTED XBRL INSTANCE DOCUMENT vnda630201910q_htm.xml XML 1194868
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 19990871
SIC: 2834 Pharmaceutical Preparations